Benign Prostatic Hyperplasia (BPH) is an age-related enlargement of the prostate gland that commonly affects men over 40. The condition results from hyperplasia of prostatic stromal and epithelial cells, leading to compression of the prostatic urethra and bladder outlet obstruction.
In its early stages, BPH appears mild and manageable. Many men experience occasional urinary symptoms and assume it is simply part of ageing.
However, BPH is a growing concern.
In approximately the first 60% of its course, BPH behaves as a bothersome but largely benign condition:
During this stage, symptoms fluctuate and may respond temporarily to medication.
But in the later 30-40% of the disease progression, untreated or poorly monitored BPH can lead to serious and sometimes irreversible complications, including:
What begins as a lifestyle inconvenience can evolve into a life-threatening condition.
BPH is not prostate cancer. It is a benign enlargement related to ageing and hormonal influences. However, prostate cancer and BPH may coexist in some individuals, which makes specialist evaluation essential. It is equally important to understand that BPH remains a progressive disease even when a patient is on medication. Medicines may relieve symptoms but do not necessarily halt structural progression. Over time, obstruction can silently worsen and lead to bladder dysfunction, kidney impairment or infections. Early and structured monitoring prevents irreversible damage and ensures timely intervention.
Conventional surgical procedures, such as TURP and some laser treatments, may impact ejaculation due to retrograde flow.
Modern ejaculation-preserving procedures are specifically designed to reduce this risk while effectively relieving obstruction.
Early evaluation allows for minimally invasive treatment options before complications develop.
A structured and evidence-based assessment may include a thorough evaluation to determine the stage of the disease and help prevent complications.
Dr. Priyaddarshi Ranjan is a renowned urologist with over 20 years of experience in advanced prostate care. He is among the early pioneers in India to adopt minimally invasive therapies such as UroLift, Rezum and iTind, bringing internationally recognised ejaculation-preserving techniques to the region. His approach focuses on precise evaluation, early intervention and long-term preservation of urinary and sexual health.
With advanced training at Johns Hopkins in the United States and Birmingham NHS in the United Kingdom, Dr Ranjan has consistently introduced global standards of prostate care to his practice. His expertise in minimally invasive prostate surgery and complex robotic urological procedures has established him as a leading authority in progressive BPH management.
Personal journeys of patients who regained comfort and quality of life through Dr. Ranjan’s advanced prostate care.